Some of the companies that expressed serious concern over the impact of hew PBS pricing framework when it was announced have finally secured relief while the health department has effectively exercised discretion to exempt itself from a 22 per cent reduction.
Latest 'discretion' outcomes provide more relief, including for the health department
February 27, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Government moves on general co-pay as safety gets further out of reach
July 29, 2025 - - Latest News -
'For these families, genomics is not a luxury—it’s the only viable path'
July 29, 2025 - - Latest News -
Pharmac identifies the wider societal benefit of treatments for chronic conditions
July 28, 2025 - - Latest News -
Australian cell therapy company appoints experienced executive as CEO
July 28, 2025 - - Australian Biotech -
Alterity Therapeutics reports positive topline data from Phase 2 trial of ATH434
July 28, 2025 - - Australian Biotech -
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 - - Australian Biotech -
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech